Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.36 |
| ▸ | PDE4A | P27815 | 4/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | CCR8 | P51685 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | TPMT | P51580 | 1/20 | 0.34 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30007139 | 1.00 | KMO (0.40) | KMOKMT2APDE4DPDE4BPDE4A | |
| SCHEMBL30211305 | 0.88 | PARP1 (0.43) | KMOPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL25687961 | 0.87 | ATM (0.41) | KMOPDE4DPDE4BPDE4APDE4C | |
| SCHEMBL23905483 | 0.86 | CA12 (0.39) | KMT2APDE4DPDE4BKDM4E | |
| SCHEMBL23195900 | 0.85 | KMO (0.44) | KMOKMT2APDE4DPDE4BPDE4A | |
| SCHEMBL23904830 | 0.85 | KMT2A (0.44) | KMOKMT2APDE4DPDE4BPDE4A | |
| SCHEMBL23904835 | 0.84 | SCD (0.39) | KMOKMT2APDE4DPDE4BPDE4A | |
| SCHEMBL23905501 | 0.84 | KMT2A (0.43) | KMOKMT2APDE4DPDE4BPDE4A | |
| SCHEMBL23958594 | 0.83 | CCR1 (0.44) | KMOCCR1CCR5CCR8PARP1 | |
| SCHEMBL23904799 | 0.83 | KMT2A (0.41) | KMOKMT2APDE4DPDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| EP-4139293-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2023-03-01 | — | — | EP | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| CN-115461336-A | RSV inhibiting 3-substituted quinoline and cinnoline derivatives | 爱尔兰詹森科学公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021198981-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | Janssen Biopharma, Inc. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2021066922-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | KMO 1402/4885KMT2A 3227/4885PDE4D 4106/4885 |
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | KMO 2116/4885KMT2A 2570/4885PDE4D 2028/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | KMO 2116/4885KMT2A 2570/4885PDE4D 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.